Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
A biologic designed for the treatment of inflammatory diseases, Siliq (brodalumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate-to-severe plaque psoriasis.
Due to ... Read more
Biologics are not effective in treating everyone with psoriasis according to a study conducted by Swedish scientists. Despite ongoing systemic treatment with biologics, around on in five patients have persisting ... Read more
The addition of an immunosuppressive agent to Stelara (ustekinumab) could restore the response to treatment in psoriasis patients according to a study titled “Recapturing adequate control of psoriasis by additional ... Read more